Regeneron Posts 19% Revenue Growth in Q1, Non-GAAP EPS Up 15% Amidst GAAP Decline
REGN sits 55% above its 52-week low of $476.487.
Summary
Regeneron Pharmaceuticals reported its first-quarter 2026 financial results, showing a 19% increase in total revenues to $3.61 billion and a 15% rise in non-GAAP diluted earnings per share to $9.47. This strong top-line and non-GAAP bottom-line growth was emphasized by management. However, GAAP diluted EPS decreased by 7% to $6.75, and GAAP net income fell by 10% to $727 million. The company also provided a business update, reiterating recent positive regulatory approvals for Dupixent and Otarmeni, which were previously announced in the past week. Traders will need to assess this mixed financial performance, balancing the strong revenue and non-GAAP growth against the GAAP decline, especially following a period of significant positive pipeline news.
At the time of this announcement, REGN was trading at $736.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $77.4B. The 52-week trading range was $476.49 to $821.11. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.